Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2021-05-27 Declaration of Voting R…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
Disclosure of voting rights for Chairman of the Board
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly discusses the voting rights and share representation of the Chairman of the Board, Hans Peter Bøhn, specifically in relation to the upcoming Annual General Meeting (AGM) scheduled for May 28, 2021. This content directly relates to the structure, governance, and voting mechanics surrounding a general meeting. While it mentions the AGM, it is not the presentation (AGM-R) or the proxy materials (PSI), but rather a disclosure of a key insider's voting power. This type of disclosure regarding director/insider shareholding and voting authority, especially in the context of an AGM, aligns most closely with Director's Dealing (DIRS) or Governance Information (CGR). However, since the core subject is the disclosure of voting rights/powers held by a director/chairman for a specific meeting, and it is a mandatory disclosure under securities law, it fits best under Director's Dealing (DIRS) as it concerns insider transactions/holdings, or potentially Governance Information (CGR). Given the focus on the Chairman's voting power for the AGM, and the mention of insider status, DIRS is a strong candidate, but DVA (Declaration of Voting Results) is for *results*, not pre-meeting power disclosure. Since it details the holdings and powers of a director, DIRS is the most appropriate fit among the specific options, although it is not a typical 'trade' report. If DIRS is interpreted strictly as trades, CGR (Governance) is the next best fit for board member information. Given the context of voting rights disclosure for a director, I will classify it as Director's Dealing (DIRS) as it pertains to insider holdings/influence, or CGR. Re-evaluating the definitions: DIRS is for 'personal share transactions'. This is a disclosure of holdings and powers of attorney for voting, not a transaction. CGR is for 'internal rules, board structure, and governance practices'. This disclosure is a specific governance event related to the board structure (Chairman's role in voting). Given the options, CGR seems slightly more encompassing than DIRS for a disclosure about a director's voting capacity rather than a trade. However, the document is very short and specific, resembling a mandatory regulatory filing. Since it is a disclosure of a director's position regarding voting rights, and not a general governance report, I will lean towards the most specific category related to insider holdings/actions, which is DIRS, interpreting it broadly as insider disclosure, or RNS as a fallback. Given the specific nature of the disclosure about a director's voting power, and the lack of a perfect fit, I will select CGR as it relates to board structure/governance, or RNS as a mandatory disclosure. Since it is a specific disclosure about a director's voting rights, and not a general governance document, and it is not a trade (DIRS), I will classify it as RNS (Regulatory Filings) as a mandatory disclosure that doesn't fit the other specific categories well, or CGR. Let's choose CGR as it pertains to the governance role of the Chairman.
2021-05-27 English
PCI Biotech: Notice of Annual General Meeting 2021
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2020' for PCI Biotech Holding ASA. It contains a comprehensive overview of the company's business, technology, board report, and references financial statements. It is a full-length annual report, not an announcement or a summary. FY 2020
2021-05-07 English
PCI Biotech: Notice of Annual General Meeting 2021
Remuneration Information Classification · 98% confidence The document is explicitly titled "PCI Biotech Holding ASA ("PCI Biotech") - Remuneration Policy". It details the principles, elements (fixed pay, variable pay, benefits), benchmark review guidelines, and annual review processes specifically for executive and board compensation. This content directly aligns with the definition of a Remuneration Information document, which corresponds to the DEF 14A filing type in the provided schema, even though the document itself is a policy document rather than a definitive proxy statement filing. The mention of the policy being adopted by the AGM suggests it is a key component of governance/remuneration disclosure typically found in proxy materials or related governance reports. Given the options, 'DEF 14A' (Remuneration Information) is the most specific fit for a detailed remuneration policy.
2021-05-07 English
PCI Biotech: Notice of Annual General Meeting 2021
Governance Information Classification · 95% confidence The document is titled "Innstilling fra Valgkomitéen i PCI Biotech Holding ASA" (Proposal from the Nomination committee of PCI Biotech Holding ASA) dated May 5, 2021. It details the committee's work, proposes the re-election of the Chairman and all board members, suggests their remuneration, and also proposes the re-election and remuneration for the nomination committee itself. This content directly relates to the composition of the board and the process leading up to shareholder voting on these matters, which falls under the scope of governance and board structure information, often presented ahead of an Annual General Meeting (AGM). However, the specific content—a proposal from the Nomination Committee regarding board elections and remuneration—is a key component of the materials presented to shareholders for approval, which is often covered by Proxy Statements (PSI) or Governance Reports (CGR). Given the focus on board composition, elections, and remuneration proposals, it strongly aligns with Governance Information (CGR) or Proxy Solicitation (PSI). Since it is a formal proposal from the Nomination Committee regarding board structure and compensation, CGR (Governance Information) is a strong fit, as it details internal rules/structure. If this were the actual voting result, it would be DVA. If it were the full proxy statement, it would be PSI. As it is the Nomination Committee's recommendation document, CGR is the most appropriate fit among the provided options, as it details the proposed governance structure.
2021-05-07 English
PCI Biotech: Notice of Annual General Meeting 2021
AGM Information Classification · 100% confidence The document is explicitly titled "PROPOSED RESOLUTIONS FOR THE ANNUAL GENERAL MEETING 28 May 2021". It details specific items to be voted upon at a general meeting, such as the election of a chairperson, approval of the annual report, election of the board, determination of remuneration, and authorizations for capital increases. These items are characteristic of the agenda and proposals presented for shareholder approval at an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2021-05-07 English
PCI Biotech: Notice of Annual General Meeting 2021
AGM Information Classification · 99% confidence The document is explicitly titled "NOTICE OF ANNUAL GENERAL MEETING OF PCI BIOTECH HOLDING ASA" and contains the agenda, date (28 May 2021), location, and instructions for shareholders regarding attendance, voting, and proxy submission for this meeting. This content directly corresponds to the materials distributed for an Annual General Meeting (AGM). Although it mentions the approval of the annual accounts and annual report (Item 4), the primary function of this document is to serve as the official notice and solicitation for shareholder participation in the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-05-07 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.